Alfred K. Cheung

Alfred K. Cheung, MD

Languages spoken: English, Cantonese

  • Alfred K. Cheung, M.D. is a Professor of Medicine, Chief of Division of Nephrology & Hypertension and Executive Director of the Dialysis Program at the University of Utah Hospital & Clinics. As a nephrologist, he manages a variety of kidney diseases, with particular interests in chronic kidney disease, hypertension and chronic dialysis. He is active in research and speaks frequently at a national level in these areas. Dr. Cheung received his M.D. degree from Albany Medical College in New York. He completed his Nephrology fellowship training from the University of California at San Diego. He is board certified in Internal Medicine and Nephrology. Dr. Cheung has been active on various committees in the American Society of Nephrology and National Kidney Foundation. He has also co-chair national practice guidelines.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Nephrology)
    National Board of Medical Examiners

  • Alfred K. Cheung, M.D. is a Professor of Medicine, Chief of Division of Nephrology & Hypertension and Executive Director of the Dialysis Program at the University of Utah Hospital & Clinics. As a nephrologist, he manages a variety of kidney diseases, with particular interests in chronic kidney disease, hypertension and chronic dialysis. He is active in research and speaks frequently at a national level in these areas. Dr. Cheung received his M.D. degree from Albany Medical College in New York. He completed his Nephrology fellowship training from the University of California at San Diego. He is board certified in Internal Medicine and Nephrology. Dr. Cheung has been active on various committees in the American Society of Nephrology and National Kidney Foundation. He has also co-chair national practice guidelines.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Nephrology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Nephrology)
    National Board of Medical Examiners

    Education history

    Fellowship Research Nephrology - University of California - San Diego Fellow
    Clinical Nephrology - University of California - San Diego Fellow
    Residency Internal Medicine - Loma Linda University Resident
    Loma Linda University Intern
    Professional Medical Medicine - Albany Medical College M.D.
    State University of New York B.A.

    Selected Publications

    Journal Article

    1. Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C (2019). Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Circ Heart Fail, 12(6), e005875.
    2. Allon M, Litovsky SH, Tey JCS, Sundberg CA, Zhang Y, Chen Z, Fang Y, Cheung AK, Shiu YT (2018). Abnormalities of vascular histology and collagen fiber configuration in patients with advanced chronic kidney disease. J Vasc Access, 20(1), 31-40.
    3. Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V, SPRINT Research Group (2017). Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care.
    4. Palit S, Chonchol M, Cheung AK, Kaufman J, Smits G, Kendrick J (01/01/2015). Association of BP with death, cardiovascular events, and progression to chronic dialysis in patients with advanced kidney disease. (PMID: 25979975). Clin J Am Soc Nephrol, (10), 934-940.
    5. Kuttykrishnan S, Kalantar-Zadeh K, Arah OA, Cheung AK, Brunelli S, Heagerty PJ, Katz R, Molnar MZ, Nissenson A, Ravel V, Streja E, Himmelfarb J, Mehrotra R (01/01/2015). Predictors of treatment with dialysis modalities in observational studies for comparative effectiveness research. (PMID: 25883196). Nephrol Dial Transplant, 1208-1217.
    6. Zhou G, Liu X, Cheung AK, Huang Y (01/01/2015). Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus? (PMID: 26175845). Am J Transplant, (15), 825-840.
    7. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK (01/01/2015). Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO Study. (Epub ahead of print ). J Am Soc Nephrol, (PMID: 2597143.
    8. Yan G, Cheung AK, Greene T, Yu AJ, Oliver MN, Yu W, Ma JZ, Norris KC (01/01/2015). Interstate variation in receipt of nephrologist care in US patients approaching ESRD: race, age, and state characteristics. Clin J Am Soc Nephrol 10:1979-1988, 2015 (PMID: 26450930). Clin J Am Soc Nephrol.
    9. Terry CM, Zhuplatov I, He Y, Wun TC, Kim SE, Cheung AK (01/01/2015). Assessment of novel anti-thrombotic fusion proteins for inhibition of stenosis in a porcine model of arteriovenous graft. (PMID: 26360605). PLoS One.
    10. Mehrotra R, Soohoo M, Rivara M, Himmelfarb J, Cheung AK, Arah OA, Nissenson A, Ravel V, Streja E, Kuttykrishnan S, Katz R, Molnar MZ, Kalantar-Zadeh K (01/01/2015). Racial and ethnic disparities in utilization of and outcomes with home dialysis in the United States. J Am Soc Nephrol, (27), 2123-2134.
    11. Jovanovich AJ, Chonchol MB, Sobhi A, Kendrick JB, Cheung AK, Kaufman JS, Smits G, Jablonski KL and the HOST Investigators (01/01/2015). Mineral metabolites, angiotensin II inhibition, and outcomes in advanced chronic kidney disease. in press. Am J Nephrol.
    12. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Mahboob Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT, for the SPRINT Study Research Group (01/01/2015). A randomized trial of intensive versus standard blood pressure control. N Engl J Med.
    13. Dember LM, Imrey PB, Beck GJ, Cheung AK, Himmelfarb J, Huber TS, Kusek JW, Roy-Chaudhury P, Vazquez MA, Alpers CE, Robbin ML, Vita JA, Greene T, Gassman JJ, Feldman HI (01/01/2014). Hemodialysis Fistula Maturation Study Group: Objectives and design of the Hemodialysis Fistula Maturation Study. (PMID: 23992885). Am J Kidney Dis, (63), 104-112.
    14. Chang, TI, Flythe JE, Brunelli SM, Muntner P, Greene T, Cheung AK, Chertow GM (01/01/2014). Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. (PMID: 23803593). J Hum Hypertens, 28, 18-24.
    15. Zhou G, Cheung AK, Liu X, Huang Y (01/01/2014). Valsartan slows the progression of diabetic nephropathy in db/db mice via reduction in podocyte injury and renal oxidative stress and inflammation.(PMID: 24195695). Clin Sci (Lond), (126), 707-720.
    16. Zhang JL, Morrell G, Rusinek H, Warner L, Vivier PH, Cheung AK, Lerman LO, Lee VS (01/01/2014). Measurement of renal tissue oxygenation with blood oxygen level-dependent MRI and oxygen transit modeling. (PMID: 24452640). (306), F579-587.
    17. Zhang J, Gu C, Lawrence DA, Cheung AK, Huang Y (01/01/2014). A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes. (PMID: 24443353). Exp Physiol, (99), 802-815.
    18. Guo X, Zhou G, Guo M, Cheung AK, Huang Y, Beddhu S (01/01/2014). Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II, (PMID: 24744899). Physiol Rep, 2e00230.
    19. Yan G, Norris KC, Greene T, Yu AJ, Ma JZ, Yu W, Cheung AK (01/01/2014). Race/ethnicity, age, and risk of hospital admission and length of stay during the first year of maintenance hemodialysis, (PMID: 24948142). Clin J Am Soc Nephrol, (9), 1402-1409.
    20. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK, The SPRINT Study Research Group (01/01/2014). The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). (PMID: 24902920). Clin Trials, (11), 532-546.
    21. Terry CM, Carlson ML, He Y, Ulu A, Morisseau C, Blumenthal DK, Hammock BD, Cheung AK (01/01/2014). Aberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis model, (PMID: 25196102). J Vasc Res, (51), 269-282.
    22. Jovanovich AJ, Chonchol M, Brady CB, Kaufman JD, Kendrick J, Cheung AK, Jablonski KL (01/01/2014). 25-Vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: A veteran population, (PMID: 25208315). Clin Nephrol, (82), 296-303.
    23. Filipowicz R, Greene T, Wei G, Cheung AK, Raphael KL, Baird BC, Beddhu S (2013). Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. Clin J Am Soc Nephrol, 8(1), 26-32.
    24. 141 Montford JR, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Kendrick J (2013). Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23. Am J Nephrol, (37:183-190).
    25. Raphael KL, Zhang Y, Wei G, Greene T, Cheung AK, Beddhu S, El Nahas M (01/01/2013). Serum bicarbonate and mortality in adults in NHANES III. (PMID: 23348878). Nephrol Dial Transplant, (28), 1207-12.
    26. Yan G, Cheung AK, Ma JZ, Yu AJ, Greene T, Oliver MN, Yu W, Norris KC (01/01/2013). The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD. (PMID: 23493380). Clin J Am Soc Nephrol, (8), 610-618.
    27. Yan G, Norris KC, Yu AJ, Ma JZ, Greene T, Yu W, Cheung AK (01/01/2013). The relationship of age, race and ethnicity with survival in dialysis patients. (PMID: 23539227). Clin J Am Soc Nephrol, (8), 953-961.
    28. Sharma S, Joseph J, Chonchol M, Kaufman JS, Cheung AK, Rafeq Z, Smits G, Kendrick J (01/01/2013). Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients. (PMID: 23849306). Clin Nephrol, (80), 313-321.
    29. Yan G, Norris KC, Xin W, Ma JZ, Yu AJ, Greene T, Yu W, Cheung AK (01/01/2013). Facility size, race and ethnicity, and mortality for in-center hemodialysis. (PMID: 23970120). J Am Soc Nephrol, (24), 2062-2070.
    30. Shastri S, Tangri N, Tighiouart H, Beck GJ, Vlagopoulos P, Ornt D, Eknoyan G, Kusek JW, Herzog C, Cheung AK, Sarnak MJ (2012). Risk factors and a prediction model for sudden cardiac in the HEMO Study. Clin J Am Soc Nephrol, 7, 123-130.
    31. Brinton, MR, Tagge CA, Stewart RJ, Cheung AK, Shiu YT, Christensen DA (2012). Thermal sensitivity of endothelial cells on synthetic vascular graft material. Int J Hyperthermia, 28, 163-174.
    32. Jovanovich A, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Kendrick J, and the HOST Investigators (2012). Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clin J Am Soc Nephrol, 7, 640-647.
    33. Terry CM, Li L, Li H, Zhuplatov I, Blumenthal DK, Kim S-E, Owen SC, Kholmovski EG, Fowers KD, Rathi R, Cheung AK (2012). In vivo evaluation of the delivery and efficacy of a sirolimus-laden polymer gel for inhibition of hyperplasia in a porcine model of arteriovenous hemodialysis graft stenosis. J Control Release, 160, 459-467.
    34. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol MB, and the HOST Investigators (2012). : A biodegradable perivascular wrap for controlled, local and directed drug delivery. Am J Kidney Dis.
    35. Sanders WG, Morisseau C, Hammock BD, Cheung AK, Terry CM (2012). Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-Inflammatory effects of a soluble epoxide hydrolase inhibitor. Am J Physiol Cell Physiol.
    36. Sanders WG, Hogrebe PC, Grainger DW, Cheung AK, Terry CM (2012). A biodegradable perivascular wrap for controlled, local and directed drug delivery. J Control Release, 161, 81-89.
    37. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Study Investigators (2012). Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis, Epub ahead, of print.
    38. Chang TI, Friedman GD, Cheung AK, Greene T, Desai M, Chertow GM (2011). Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. J Hum Hypertens, 25(2), 98-105.
    39. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S (2011). Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney Int, 79(2), 228-33.
    40. Li L, Blumenthal DK, Terry CM, He Y, Carlson ML, Cheung AK (2011). PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms. J Cell Biochem, 112, 289-298.
    41. Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK (2011). Efficacy and safety of carvedilol in treatment of heart failure in chronic kidney disease: A meta-analysis of randomized trials. Circ Heart Fail, 4, 18-26.
    42. Chang, TI, Paik, J, Greene T, Desai M, Bech F, Cheung AK, Chertow GM (2011). Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol, 22, 1526-1533.
    43. Chang TI, Shilane D, Brunelli SM, Cheung AK, Chertow GM, Winkelmayer WC (2011). Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J, 162, 324-330.
    44. Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, Nahas ME, Feldt-Rasmussen B, Mitch WE, Wanner C, Gthberg M, T Ikizler TA (2011). OPPORTUNITYTM: A large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant, 26, 4095-4103.
    45. Tangri N, Shastri S, Tighiouart H, Beck GJ, Cheung AK, Eknoyan G, Sarnak MJ (2011). Beta-blockers for prevention of sudden cardiac death in patients on hemodialysis: A propensity score analysis of the HEMO Study. Am J Kidney Dis, 58, 939-945.
    46. Agar BU, Akonur A, Cheung AK, Leypoldt JK (2011). A simple method to estimate phosphorus mobilization in hemodialysis using only predialytic and postdialytic blood samples. Hemodial Int, 15, S9-S14.
    47. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Investigators (2011). FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol, 22, 1913-1922.
    48. Agar BU, Akonu RA, Lo Y-C, Cheung AK, Leypoldt JK (2011). Kinetic model of phosphorus mobilization during and after short and conventional hemodialysis. Clin J Am Soc Nephrol, 6, 2854-2860.
    49. Brinton MR, Stewart RJ, Cheung AK, Christensen DA, Shiu Y-T E (2011). Modelling ultrasound-induced mild hyperthermia of hyperplasia in vascular grafts. Theor Biol Med Model, 8, 42.
    50. Owen SC, Li H, Sanders WG, Cheung AK, Terry CM (2010). Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft. J Control Release, 146(1), 23-30.
    51. Beddhu S, Baird B, Ma X, Cheung AK, Greene T (2010). Serum alkaline phosphatase and mortality in hemodialysis patients. Clin Nephrol, 74(2), 91-6.
    52. Huang CX, Tighiouart H, Beddhu S, Cheung AK, Dwyer JT, Eknoyan G, Beck GJ, Levey AS, Sarnak MJ (2010). Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int, 77(7), 624-9.
    53. Beddhu S, Ma X, Baird B, Cheung AK, Greene T (2009). Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol, 4(11), 1805-10.
    54. Zhu W, Masaki T, Cheung AK, Kern SE (2009). In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation. J Bioequivalence Bioavailab, 1, 3-12.
    55. Preston JS, Tasdizen T, Terry CM, Cheung AK, Kirby RM (2009). Using the stochastic collocation method for the uncertainty quantification of drug concentration due to depot shape variability. IEEE Trans Biomed Eng, 56(3), 609-20.
    56. Goldfarb-Rumyantzev AS, Chelamcharla M, Bray BE, Leypoldt JK, Lavasani I, Nelson N, Lavasani T, Baird B, Cheung AK (2009). Volume indicators and left ventricular mass during aggressive volume management in patients on thrice-weekly hemodialysis. Nephron Clin Pract, 113(4), c270-80.
    57. Terry CM, Kim SE, Li L, Goodrich KC, Hadley JR, Blumenthal DK, Parker DL, Cheung AK (2009). Longitudinal assessment of hyperplasia using magnetic resonance imaging without contrast in a porcine arteriovenous graft model. Acad Radiol, 16(1), 96-107.
    58. Naiman N, Cheung AK, Goldfarb-Rumyantzev AS (2009). Familiality of cardiovascular mortality in end-stage renal disease patients. Am J Nephrol, 29(3), 237-43.
    59. Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, Lange M, Mitch WE, Wanner C, Wiedemann J, Ikizler TA (2008). OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol, 3(6), 1741-51.
    60. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC (2008). Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis, 52(3), 531-40.
    61. Munger MA, Gardner SF, Ateshkadi A, Rabetoy GM, Barri YM, Stoddard GJ, Cheung AK (2008). Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study. Pharmacotherapy, 28(7), 834-42.
    62. Cheung AK, Terry C, Li L (2008). Pathogenesis and local drug delivery for prevention of vascular access stenosis. J Ren Nutr, 18(1), 140-5.
    63. Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G (2008). Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol, 3(1), 69-77.
    64. Beddhu S, Cheung AK, Larive B, Greene T, Kaysen GA, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G (2007). Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. J Ren Nutr, 17(6), 372-80.
    65. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK (2007). The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis, 50(5), 791-802.
    66. Li L, Terry CM, Blumenthal DK, Kuji T, Masaki T, Kwan BC, Zhuplatov I, Leypoldt JK, Cheung AK (2007). Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant, 22(11), 3139-46.
    67. Kuji T, Masaki T, Li L, Cheung AK (2007). Expression of C-reactive protein in myointimal hyperplasia in a porcine arteriovenous graft model. Nephrol Dial Transplant, 22(9), 2469-75.
    68. Ramkumar N, Murtaugh MA, Cheung AK, Beddhu S (2007). Lack of synergistic effects of metabolic syndrome and plasma fibrinogen on coronary events and mortality in moderate CKD. Am J Kidney Dis, 49(3), 356-64.
    69. Chonchol M, Goldenberg I, Moss AJ, McNitt S, Cheung AK (2007). Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol, 27(1), 7-14.
    70. Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK (2006). Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem, 99(6), 1553-63.
    71. Zhuplatov SB, Masaki T, Blumenthal DK, Cheung AK (2006). Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation. Basic Clin Pharmacol Toxicol, 99(6), 431-9.
    72. Thekkedath UR, Chirananthavat T, Leypoldt JK, Cheung AK, Mohammad SF (2006). Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa. Am J Hematol, 81(12), 915-26.
    73. Terry CM, Blumenthal DK, Sikharam S, Li L, Kuji T, Kern SE, Cheung AK (2006). Evaluation of histological techniques for quantifying haemodialysis arteriovenous (AV) graft hyperplasia. Nephrol Dial Transplant, 21(11), 3172-9.
    74. Zhu W, Masaki T, Cheung AK, Kern SE (2006). Cellular pharmacokinetics and pharmacodynamics of dipyridamole in vascular smooth muscle cells. Biochem Pharmacol, 72(8), 956-64.
    75. Lee RM, Masaki T, Yang HS, Liu J, Chen J, Li L, Blumenthal DK, Cheung AK (2006). Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells. J Cell Biochem, 99(3), 835-44.
    76. Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS (2006). The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant, 21(10), 2881-92.
    77. Kuji T, Masaki T, Goteti K, Li L, Zhuplatov S, Terry CM, Zhu W, Leypoldt JK, Rathi R, Blumenthal DK, Kern SE, Cheung AK (2006). Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney Int, 69(12), 2179-85.
    78. Goldfarb-Rumyantzev AS, Hurdle JF, Baird BC, Stoddard G, Wang Z, Scandling JD, Barenbaum LL, Cheung AK (2006). The role of pre-emptive re-transplant in graft and recipient outcome. Nephrol Dial Transplant, 21(5), 1355-64.
    79. Goteti K, Masaki T, Kuji T, Leypoldt JK, Cheung AK, Kern SE (2006). Perivascular tissue pharmacokinetics of dipyridamole. Pharm Res, 23(4), 718-28.
    80. Zhu W, Masaki T, Bae YH, Rathi R, Cheung AK, Kern SE (2006). Development of a sustained-release system for perivascular delivery of dipyridamole. J Biomed Mater Res B Appl Biomater, 77(1), 135-43.
    81. Kwan BC, Beddhu S, Kronenberg F, Cheung AK (2006). Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis? Nat Clin Pract Nephrol, 2(2), 76-7.
    82. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G (2006). Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol, 17(2), 546-55.
    83. Goldfarb-Rumyantzev AS, Cheung AK, Habib AN, Wang BJ, Lin SJ, Baird BC, Naiman N, Cannon-Albright L (2006). A population-based assessment of the familial component of chronic kidney disease mortality. Am J Nephrol, 26(2), 142-8.
    84. Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK, Kaysen GA, Levey AS, Sarnak MJ, Schwab SJ (2006). Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Am J Kidney Dis, 47(1), 131-8.
    85. Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N, Kutner NG, Cheung AK (2006). A crossover study of short daily haemodialysis. Nephrol Dial Transplant, 21(1), 166-75.
    86. Beddhu S, Kimmel PL, Ramkumar N, Cheung AK (2005). Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis, 46(4), 577-86.
    87. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK (2005). The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant, 20(8), 1693-701.
    88. Ramkumar N, Beddhu S, Eggers P, Pappas LM, Cheung AK (2005). Patient preferences for in-center intense hemodialysis. Hemodial Int, 9(3), 281-95.
    89. Chelamcharla M, Leypoldt JK, Cheung AK (2005). Dialyzer membranes as determinants of the adequacy of dialysis. Semin Nephrol, 25(2), 81-9.
    90. Rocco MV, Cheung AK, Greene T, Eknoyan G (2005). The HEMO Study: applicability and generalizability. Nephrol Dial Transplant, 20(2), 278-84.
    91. Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, Cheung AK (2005). Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant, 20(1), 167-75.
    92. Kim S-J, Masaki T, Rowley R, Leypoldt JK, Mohammad SF, Cheung AK (2005). Different responses by cultured aortic and venous smooth muscle cells to radiation. Kidney Int, 68, 371-377.
    93. Masaki T, Rathi R, Zentner G, Leypoldt JK, Mohammad SF, Burns GL, Li L, Zhuplatov S, Chirananthavat T, Kim SJ, Kern S, Holman J, Kim SW, Cheung AK (2004). Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int, 66(5), 2061-9.
    94. Ramkumar N, Cheung AK, Pappas LM, Roberts WL, Beddhu S (2004). Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr, 14(4), 201-7.
    95. Leypoldt JK, Cheung AK, Deeter RB, Goldfarb-Rumyantzev A, Greene T, Depner TA, Kusek J (2004). Kinetics of urea and beta-microglobulin during and after short hemodialysis treatments. Kidney Int, 66(4), 1669-76.
    96. Kim SJ, Masaki T, Leypoldt JK, Kamerath CD, Mohammad SF, Cheung AK (2004). Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs. J Lab Clin Med, 144(3), 156-62.
    97. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS (2004). Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int, 65(6), 2380-9.
    98. Masaki T, Kamerath CD, Kim SJ, Leypoldt JK, Mohammad SF, Cheung AK (2004). In vitro pharmacological inhibition of human vascular smooth muscle cell proliferation for the prevention of hemodialysis vascular access stenosis. Blood Purif, 22(3), 307-12.
    99. Depner TA, Greene T, Daugirdas JT, Cheung AK, Gotch FA, Leypoldt JK (2004). Dialyzer performance in the HEMO Study: in vivo K0A and true blood flow determined from a model of cross-dialyzer urea extraction. ASAIO J, 50(1), 85-93.
    100. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G (2003). Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol, 14(12), 3251-63.
    101. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Ramkumar N, Pappas LM, Cheung AK (2003). Impact of timing of initiation of dialysis on mortality. J Am Soc Nephrol, 14(9), 2305-12.
    102. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK (2003). Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol, 14(4), 1000-5.
    103. Leypoldt JK, Cheung AK, Chirananthavat T, Gilson JF, Kamerath CD, Deeter RB (2003). Hollow fiber shape alters solute clearances in high flux hemodialyzers. ASAIO J, 49(1), 81-7.
    104. 68 Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung A, Muhlestein JB for the Intermountain Heart Collaborative Study Group (2003). Do Associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol, 42, 57-63.
    105. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R (2002). Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med, 347(25), 2010-9.
    106. Goldfarb-Rumyantzev AS, Cheung AK, Leypoldt JK (2002). Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Am J Kidney Dis, 40(6), 1211-8.
    107. Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, Anderson JL (2002). Impact of renal failure on the risk of myocardial infarction and death. Kidney Int, 62(5), 1776-83.
    108. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK (2002). Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis, 40(4), 721-7.
    109. Cheung AK, Yan G, Greene T, Daugirdas JT, Dwyer JT, Levin NW, Ornt DB, Schulman G, Eknoyan G (2002). Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients. J Am Soc Nephrol, 13(9), 2345-52.
    110. Leypoldt JK, Cheung AK (2002). Optimal use of hemodialyzers. Contrib Nephrol, (137), 129-37.
    111. Bergstrom J, Lysaght M, Cheung AK (2002). The career of Lee W. Henderson. J Am Soc Nephrol, 13 Suppl 1, S1-2.
    112. Leypoldt JK, Cheung AK, Delmez JA, Gassman JJ, Levin NW, Lewis JA, Lewis JL, Rocco MV (2002). Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int, 61(1), 266-75.
    113. Leypoldt JK, Cheung AK (2001). Increases in mass transfer-area coefficients and urea Kt/V with increasing dialysate flow rate are greater for high-flux dialyzers. Am J Kidney Dis, 38(3), 575-9.
    114. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK (2001). Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol, 21(4), 280-8.
    115. Peng H, Cheung AK, Reimer LG, Kamerath CD, Leypoldt JK (2001). Effect of indomethacin on peritoneal protein loss in a rabbit model of peritonitis. Kidney Int, 59(1), 44-51.
    116. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS (2000). Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int, 58(1), 353-62.
    117. Munger MA, Ateshkadi A, Cheung AK, Flaharty KK, Stoddard GJ, Marshall EH (2000). Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers. Am J Kidney Dis, 36(1), 130-9.
    118. Luo Q, Cheung AK, Kamerath CD, Reimer LG, Leypoldt JK (2000). Increased protein loss during peritonitis associated with peritoneal dialysis is neutrophil dependent. Kidney Int, 57(4), 1736-42.
    119. Kozek-Langenecker SA, Mohammad SF, Masaki T, Kamerath C, Cheung AK (2000). The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg, 90(4), 808-12.
    120. Kozek-Langenecker SA, Mohammad SF, Masaki T, Green W, Kamerath C, Cheung AK (2000). The effects of aprotonin on platelets in vitro using whole blood flow cytometry. Anesth Analg, 90(1), 12-6.
    121. Leypoldt JK, Cheung AK, Deeter RB (1999). Rebound kinetics of beta2-microglobulin after hemodialysis. Kidney Int, 56(4), 1571-7.
    122. Yarar D, Cheung AK, Sakiewicz P, Lindsay RM, Paganini EP, Steuer RR, Leypoldt JK (1999). Ultrafiltration method for measuring vascular access flow rates during hemodialysis. Kidney Int, 56(3), 1129-35.
    123. Kozek-Langenecker SA, Masaki T, Mohammad H, Green W, Mohammad SF, Cheung AK (1999). Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int, 56(1), 299-305.
    124. Masaki T, Gilson J, Leypoldt JK, Cheung AK (1999). Effect of permeability on indices of haemodialysis membrane biocompatibility. Nephrol Dial Transplant, 14(5), 1176-81.
    125. Cheung AK, Agodoa LY, Clark W, Daugirdas, JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK, and the Hemodialysis HEMO Study (1999). Effects of hemodialyzer reuse on clearances of urea and ß2-microglobulin. J Am Soc Nephrol, 10, 117-127.
    126. Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJG, Agodoa LY, Port FK (1999). Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis, 33, 349-355.
    127. Leypoldt JK, Cheung AK (1999). The effect of low dialysate flow rate on hemodialyzer mass transfer-area coefficients of urea and creatinine. Home Hemodial Int (1997), 3, 51-54.
    128. Leypoldt JK, Cheung AK, Deeter RB (1998). Effect of hemodialyzer reuse: dissociation between clearances of small and large solutes. Am J Kidney Dis, 32(2), 295-301.
    129. Steuer RR, Germain MJ, Leypoldt JK, Cheung AK (1998). Enhanced fluid removal guided by blood volume monitoring during chronic hemodialysis. Artif Organs, 22(8), 627-32.
    130. Leypoldt JK, Cheung AK, Deeter RB (1997). Single compartment models for evaluating beta 2-microglobulin clearance during hemodialysis. ASAIO J, 43(6), 904-9.
    131. Moser L, Callahan KS, Cheung AK, Stoddard GJ, Munger MA (1997). ACE inhibitor effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol, 30(4), 461-7.
    132. Morton KA, Pisani DE, Whiting JH Jr, Cheung AK, Arias JM, Valdivia S (1997). Determination of glomerular filtration rate using technetium-99m-DTPA with differing degrees of renal function. J Nucl Med Technol, 25(2), 110-4.
    133. Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, Greene T, Keshaviah PR (1997). Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Hemodialysis (HEMO) Study. Kidney Int, 51(6), 2013-7.
    134. Cheung AK, Leypoldt JK (1997). The hemodialysis membranes: a historical perspective, current state and future prospect. Semin Nephrol, 17(3), 196-213.
    135. Ing TS, Cheung AK, Golper TA, Lang GR, Lazarus JM, Letteri JM, Levin NW, Lundin AP, Molony DA, Mujais SK, Port FK, Ward RA (1997). National Kidney Foundation report on dialyzer reuse. Am J Kidney Dis, 30, 859-871.
    136. Cheung AK, Parker CJ, Ren K, Iverius PH (1996). Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int, 49(5), 1360-71.
    137. Steuer RR, Leypoldt JK, Cheung AK, Senekjian HO, Conis JM (1996). Reducing symptoms during hemodialysis by continuously monitoring the hematocrit. Am J Kidney Dis, 27(4), 525-32.
    138. Leypoldt JK, Cheung AK (1996). Removal of high-molecular-weight solutes during high-efficiency and high-flux haemodialysis. Nephrol Dial Transplant, 11(2), 329-35.
    139. Leypoldt JK, Charney DI, Cheung AK, Naprestek CL, Akin BH, Shockley TR (1995). Ultrafiltration and solute kinetics using low sodium peritoneal dialysate. Kidney Int, 48(6), 1959-66.
    140. Leypoldt JK, Cheung AK, Steuer RR, Harris DH, Conis JM (1995). Determination of circulating blood volume by continuously monitoring hematocrit during hemodialysis. J Am Soc Nephrol, 6(2), 214-9.
    141. Cheung AK, Parker CJ, Hohnholt M (1994). Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int, 46(6), 1680-7.
    142. Steuer RR, Leypoldt JK, Cheung AK, Harris DH, Conis JM (1994). Hematocrit as an indicator of blood volume and a predictor of intradialytic morbid events. ASAIO J, 40(3), M691-6.
    143. Cheung AK, Faezi-Jenkin B, Leypoldt JK (1994). Effect of thrombosis on complement activation and neutrophil degranulation during in vitro hemodialysis. J Am Soc Nephrol, 5(1), 110-5.
    144. Cheung AK, Wu LL, Kablitz C, Leypoldt JK (1993). Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis, 22(2), 271-6.
    145. Cheung AK, DeVault GA Jr, Gregory MC (1993). A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol, 3(12), 1884-91.
    146. Cheung AK, Parker CJ, Hohnholt M (1993). Beta2 integrins are required for neutrophil degranulation induced by hemodialysis membranes. Kidney Int, 43(3), 649-60.
    147. Leypoldt JK, Gilson JF, Blindauer KM, Cheung AK (1992). Macromolecule adsorption to hemodialysis membranes depends on molecular size. Blood Purif, 10(1), 53-60.

    Review

    1. Isakova T, Ix JH, Sprague SM, Raphael KL Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA (2015). Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD (PMID: 25967123). [Review]. J Am Soc Nephrol, 26, 2328-2339.
    2. Zhang JL, Morrell G, Rusinek H, Sigmund EE, Chandarana H, Lerman LO, Prasad PV, Niles D, Artz N, Fain S, Vivier PH, Cheung AK, Lee VS (01/01/2014). New magnetic resonance imaging methods in nephrology (PMID: 24067433). [Review]. Kidney Int, 85, 768-778.
    3. Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J (01/01/2014). GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration, 64:821-835 (PMID: 25441437). [Review]. Am J Kidney Dis.
    4. Okusa MD, Molitoris BA, Palevsky PM, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Faubel S, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (2012). Design of clinical trials in acute kidney injury: A report from an NIDDK Workshop – prevention trials. [Review]. Clin J Am Soc Nephrol, Epub ahead, of print.
    5. Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (2012). Design of clinical trials in AKI: A Report from an NIDDK Workshop. Trials of patients with sepsis and in selected hospital settings. [Review]. Clin J Am Soc Nephrol, Epub ahead, of print.
    6. Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (2012). Design of clinical trials in acute kidney injury: Report from an NIDDK Workshop on trial methodology. [Review]. Clin J Am Soc Nephrol, Epub ahead, of print.
    7. Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (01/01/2012). Design of clinical trials in AKI: A Report from an NIDDK Workshop. Trials of patients with sepsis and in selected hospital settings (PMID: 22442184). [Review]. Clin J Am Soc Nephrol, 7, 856-860.
    8. Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (01/01/2012). Design of clinical trials in acute kidney injury: Report from an NIDDK Workshop on trial methodology. 7:844-850, (PMID: 22442182). [Review]. Clin J Am Soc Nephrol.
    9. Raphael KL, Cheung AK (2011). Implications of the Frequent Hemodialysis Network-Daily Trial. [Review]. Semin Dial, 24, 621-628.
    10. Redon J, Martinez F, Cheung AK (2010). Special considerations for antihypertensive agents in dialysis patients. [Review]. Blood Purif, 29(2), 93-8.
    11. Cheung AK (2009). Is lipid control necessary in hemodialysis patients? [Review]. Clin J Am Soc Nephrol, 4 Suppl 1, S95-101.
    12. Cheung AK (2009-present). Contributing author on several topics. [Review].
    13. Li L, Terry CM, Shiu YT, Cheung AK (2008). Neointimal hyperplasia associated with synthetic hemodialysis grafts. [Review]. Kidney Int, 74(10), 1247-61.
    14. Kwan BC, Kronenberg F, Beddhu S, Cheung AK (2007). Lipoprotein metabolism and lipid management in chronic kidney disease. [Review]. J Am Soc Nephrol, 18(4), 1246-61.
    15. Roy-Chaudhury P, Sukhatme VP, Cheung AK (2006). Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. [Review]. J Am Soc Nephrol, 17(4), 1112-27.
    16. Leypoldt JK, Cheung AK (2006). Revisiting the hemodialysis dose. [Review]. Semin Dial, 19(2), 96-101.
    17. Nissenson AR, Agarwal R, Allon M, Cheung AK, Clark W, Depner T, Diaz-Buxo JA, Kjellstrand C, Kliger A, Martin KJ, Norris K, Ward R, Wish J (2004). Improving outcomes in CKD and ESRD patients: carrying the torch from training to practice. [Review]. Semin Dial, 17(5), 380-97.
    18. Henderson LW, Clark WR, Cheung AK (2001). Quantification of middle molecular weight solute removal in dialysis. [Review]. Semin Dial, 14(4), 294-9.
    19. Leypoldt JK, Cheung AK (1999). Extracellular volume in nocturnal hemodialysis. [Review]. Semin Dial, 12, S50-S54.
    20. Leypoldt JK, Cheung AK (1998). Evaluating volume status in hemodialysis patients. [Review]. Adv Ren Replace Ther, 5(1), 64-74.
    21. Cheung AK, Leypoldt JK (1998). Evaluation of hemodialyzer performance. [Review]. Semin Dial, 11, 131-137.
    22. Leypoldt JK, Cheung AK (1996). Characterization of molecular transport in artificial kidneys. [Review]. Artif Organs, 20(5), 381-9.
    23. Cheung AK (1996). Stages of future technological developments in haemodialysis. [Review]. Nephrol Dial Transplant, 11 Suppl 8, 52-8.
    24. Cheung AK (1994). Complement activation as index of haemodialysis membrane biocompatibility: the choice of methods and assays. [Review]. Nephrol Dial Transplant, 9 Suppl 2, 96-103.
    25. Cheung AK, Lemke H (1994). Criteria and standardization for biocompatibility. [Review]. Nephrol Dial Transplant, 9 Suppl 2, 72-6.
    26. Cheung AK (1994). Quantitation of dialysis. The importance of membrane and middle molecules. [Review]. Blood Purif, 12(1), 42-53.
    27. Charney DI, Walton DF, Cheung AK (1994). Difficult management problems in dialysis: Impotence II. [Review]. Semin Dial, 7, 22-29.
    28. Charney DI, Walton DF, Cheung AK (1993). Atherosclerosis in chronic renal failure. [Review]. Curr Opin Nephrol Hypertens, 2(6), 876-82.
    29. Cheung AK (1993). Interactions between plasma proteins and hemodialysis membranes. [Review]. Adv Nephrol Necker Hosp, 22, 417-37.
    30. Cheung AK (1992). Clinical phenomena induced by complement and leukocyte interactions with artificial surfaces. [Review]. J Clin Apher, 7(3), 147-8.

    Book Chapter

    1. Leypoldt JK, Henderson LW, Cheung AK (2012). Middle molecules. In Ing TS, Rahman M, Kjellstrand CM (Eds.), Dialysis: History, Development and Promise. New Jersey: World Scientific Publishing.
    2. Leypoldt JK, Culleton BF, Cheung AK (2010). Hemodialysis adequacy. In Himmelfarb J, Sayegh MH (Eds.), Chronic Kidney Disease, Dialysis, and Transplantation: Companion to Brenner & Rector’s The Kidney (3rd, pp. 320-334). Philadelphia: Elsevier.
    3. Cheung, AK (2009). Hemodialysis and hemofiltration. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC (Eds.), National Kidney Foundation Primer on Kidney Diseases (5th, pp. 446-458). Philadelphia: Saunders Elsevier.
    4. Ford L, Ward RA, Cheung AK (2009). Choice of the hemodialysis membrane. In Henrich WL (Ed.), Principles and Practice of Dialysis (4th, pp. 1-11). Philadelphia: Lippincott Williams & Wilkins.
    5. Reddy B, Cheung AKH (2009). Hemodialysis. In Lai KN (Ed.), A Practical Manual of Renal Medicine: Nephrology, Dialysis and Transplantation (pp. 201-223). Imperial College Press and World Scientific Publisher.
    6. Wali R, Kaluvapalle JR, Cheung AK (2008). Complications associated with hemodialysis. In Wilcox CS (Ed.), Therapy in Nephrology and Hypertension (Companion to Brenner & Rector’s The Kidney) (3rd edition, pp. 891-912). Philadelphia: Elsevier Saunders.
    7. Cheung AK (2005). Hemodialysis and hemofiltration. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC. Saunders (Eds.), National Kidney Foundation Primer on Kidney Diseases (4th edition, pp. 464-476). Philadelphia: Elsevier.
    8. Cheung AK (2001). Hemodialysis and hemofiltration. In: National Kidney Foundation Primer on Kidney Diseases. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC (Eds.), National Kidney Foundation Primer on Kidney Diseases (3rd, pp. 396-404). San Diego: Academic Press.
    9. Greene T, Cheung AK, Krediet R (2001). : The design of randomized clinical trials in dialysis patients. In Horl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF (Eds.), Replacement of Renal Function by Dialysis (5th, pp. 1521-1542). Dordrecht/Boston/London: Kluwer Academic Press.
    10. Pereira BG, Cheung AK (2000). Biocompatibility of hemodialysis membrane. In Owen WF, Pereira BJG, Sayegh MH (Eds.), Dialysis and Transplantation: A Companion to Brenner & Rector's The Kidney (pp. 32-56). Philadelphia: WB Saunders.
    11. Pereira BJG, Cheung AK (2000). Complications of biocompatibility of hemodialysis membranes. In Lameire NH, Mehta RL (Eds.), Complications of Dialysis (pp. 41-68). New York: Marcel Dekker.
    12. Leypoldt JK, Cheung AK Fluid removal during hemodialysis (1999). Fluid removal during hemodialysis. In Leypoldt JK. RG Landes (Ed.), The Artificial Kidney: Physiological modeling and tissue engineering (pp. 1-23).
    13. Ambalavanan S, Rabetoy G, Cheung A (1999). High efficiency and high flux hemodialysis. In Schrier RW (Ed.), Atlas of diseases of the kidney (3, pp. 1-3.10). Philadelphia.
    14. Cheung AK (1998). Hemodialysis and hemofiltration. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC (Eds.), National Kidney Foundation Primer on Kidney Diseases (2nd, pp. 408-415). San Diego: Academic Press.
    15. Leypoldt JK, Cheung AK (1998). Dialyzer reprocessing and solute clearances. In Association for the Advancement of Medical Instrumentation Standards and Recommended Practices (3, pp. 333-339).
    16. Walton DF, Cheung AK (1997). Membrane biocompatibility. In Suki WN, Massry SG (Eds.), Therapy of renal diseases and related disorders (3rd, pp. 1029-1042). Kluwer Academic Publishers.
    17. Cheung AK, Mohammad SF, Leypoldt JK (1997). Adhesion molecules and artificial membranes. In Paul LC, Issekutz TB (Eds.), Targetting cell adhesion molecules for therapeutic application (pp. 643-678). New York.
    18. Walton DF, Cheung AK (1995). Membrane biocompatibility. In Nissenson AR, Fine RN, Gentile DE (Eds.), Clinical dialysis (3rd). Norwalk: Appleton & Lange.
    19. Cheung AK (1994). Hemodialysis and hemofiltration. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC (Eds.), National Kidney Foundation Primer on Kidney Diseases (1, pp. 258-265). San Diego: Academic Press.
    20. Cheung AK (1993). Dialyzer biocompatibility: Practical considerations. In Nissenson AR, Fine RN (Eds.), Dialysis Therapy (2nd, pp. 75-77). Hanley & Belfus, Inc.

    Case Report

    1. Loghman-Adham M, Walton D, Iverius PH, Deiss A, Knight JA, Cheung AK (1997). Spurious hypophosphatemia in a patient with multiple myeloma. Am J Kidney Dis, 30(4), 571-5.
    2. Beckwith C, Flaharty KK, Cheung AK, Beatty PG (1993). Fanconi's syndrome due to ifosfamide. Bone Marrow Transplant, 11(1), 71-3.

    Editorial

    1. Chang TI, Cheung AK, Chertow GM (2010). Blood pressure control in type 2 diabetes mellitus. Am J Kidney Dis, 56(6), 1029-31.
    2. Cheung AK, Greene T (2009). Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol, 20(3), 462-4.
    3. Henderson LW, Leypoldt JK, Lysaght MJ, Cheung AK (1997). Death on dialysis and the time/flux trade-off. Blood Purif, 15(1), 1-14.
    4. Cheung AK (1994). Biocompatibility of Dialysis membrane: Practical considerations. International Yearbook of Nephrology Dialysis Transplantation, 139-149.

    Other

    1. Cheung AK, Ward RA (2011). ASN Renal Weekends slide set, American Society of Nephrology. ASN Renal Weekends slide set. American Society of Nephrology.
    2. Levin NW, Kotanko P, Eckardt KU, Kasiske BL, Chazot C, Cheung AK, Redon J, Wheeler DC, Zoccali C, London GM (2010). Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int (77(4), pp. 273-84). United States.